NKG2D checkpoint inhibitor (Novelogics Biotechnology)

N/A

Report date: 2025/03/20 15:45:54

Base Information

Drug NameNKG2D checkpoint inhibitor (Novelogics Biotechnology)
Drug Alias Namemonoclonal antibody (Novelogics Biotechnology)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionNKG2D ligands antagonists
TargetsNKG2D ligands
Therapy Area/IndicationsProstatic NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNovelogics Biotechnology Inc
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A